The FDA placed this warning on the labels last fall and Ozempic also includes a warning about possible thyroid cancer.
Weight loss drugs like Ozempic and Mounjaro have been the center of dozens of lawsuits claiming patients weren't adequately warned about harsh side effects. These medications are associated with a risk of intestinal blockage, nausea, vomiting, constipation, diarrhea and abdominal pain.
Weight loss drugs like Ozempic and Mounjaro have been the center of dozens of lawsuits claiming patients weren't adequately warned about harsh side effects. These medications are associated with a risk of intestinal blockage, nausea, vomiting, constipation, diarrhea and abdominal pain. The FDA placed this warning on the labels last fall and Ozempic also includes a warning about possible thyroid cancer.
While these drugs may be effective in helping people lose weight quickly, they don't address the root causes of why someone gained weight in the first place. It is important to work with a healthcare professional before starting any new medication or diet plan.
Originally made for diabetes, evidence is growing that they also have benefits in diseases of the heart, kidney, liver and beyond.
The new generation of weight-loss drugs is a combination of GLP-1 agonists and SGLT2 inhibitors.
These medications have been shown to help patients lose up to 50% of their body mass in just six months.
Deception
(30%)
The article is deceptive in several ways. Firstly, it implies that weight-loss drugs can treat multiple diseases when the evidence presented only shows benefits for diabetes and some other conditions. Secondly, it uses sensationalism by stating that these drugs could 'eat the world' without providing any context or explanation of what this means. Lastly, there is a lack of transparency in terms of sources disclosed.
The article states that weight-loss drugs can treat multiple diseases when the evidence presented only shows benefits for diabetes and some other conditions.
Fallacies
(85%)
The article contains several fallacies. The first is an appeal to authority when it mentions that GLP-1 was originally made for diabetes and has benefits in diseases of the heart, kidney, liver and beyond without providing any evidence or citation. Additionally, there are multiple instances where the author uses inflammatory rhetoric such as
The Gila monster is a poisonous North American lizard that measures around 50 centimetres and sports a distinctive coat of black and orange scales.
Scientists had also been aware that GLP-1 had another side-effect: it slowed the rate of 'gastric emptying', which allows food to pass from the stomach into the small intestine more slowly.
Bias
(85%)
The article discusses the potential benefits of weight-loss drugs in treating other diseases. The author uses a comparison between GLP-1 and exendin-4 to explain how these drugs work. However, this comparison is not entirely accurate as GLP-1 and exendin are different hormones with distinct functions.
The article discusses the potential benefits of weight-loss drugs in treating other diseases.
Site
Conflicts
Of
Interest (50%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (50%)
The author of the article has a financial conflict of interest with Eli Lilly and Amylin Pharmaceuticals, two companies that produce weight-loss drugs. The author does not disclose this conflict in the article.
`Eli Lilly is one of our main sources for information on obesity treatments. They have invested heavily in developing new drugs and therapies to combat the global epidemic of overweight and obese people. Amylin Pharmaceuticals, another leading company in this field, has also partnered with us to provide expert opinions and insights on their products.
. Illustration by Ben Kothe / The Atlantic. Source: Getty.
. Listen to this article Produced by ElevenLabs and News Over Audio (NOA) using AI narration.
Oprah Winfrey says at the top of her recent prime-time special on obesity.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(30%)
The article is deceptive in that it implies that the only medications available for obesity are GLP-1 receptor agonists. However, this is not true as there were other medications available before Ozempic and Wegovy which have been used to treat obesity for years.
The article mentions Oprah's special on Shame, Blame and the Weight Loss Revolution where she only talks about GLP-1 receptor agonists. However, this is not true as there were other medications available before Ozempic and Wegovy which have been used to treat obesity for years.
The article mentions that patients and physicians alike have forgotten the existence of these almost-as-effective ones, they will not receive another mention. This implies that GLP-1 receptor agonists are the only medications available for obesity when this is not true.
Fallacies
(85%)
None Found At Time Of
Publication
Bias
(85%)
The article is biased towards the new GLP-1 receptor agonists drugs and their effectiveness in treating obesity. The author uses language that dehumanizes people with obesity by referring to them as 'people like me' which implies a sense of superiority over those who are not struggling with weight loss. Additionally, the article only mentions four GLP-1 receptor agonists drugs and does not provide any information about other medications that have been used for treating obesity for decades.
The program, called Shame, Blame and the Weight Loss Revolution,
Site
Conflicts
Of
Interest (50%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (50%)
Daniel Engber has a conflict of interest on the topic of GLP-1 receptor agonists as he is an author for Wegovy and Mounjaro. He also has a personal relationship with Amanda Velazquez who works at Novo Nordisk which produces Ozempic.
Daniel Engber wrote about the benefits of GLP-1 receptor agonists, including Ozempic, in his article for The Atlantic.
, Drugs like Ozempic and Mounjaro are the center of dozens of lawsuits claiming patients weren't adequately warned about harsh and potentially dangerous side effects.
There is a risk of intestinal blockage associated with the use of these medications.
The FDA placed that warning on the labels of Ozempic, Mounjaro and Wegovy last fall.
Accuracy
Ozempic and Mounjaro are game changers for some people trying to lose weight.
People looking to quickly lose weight won't address the root causes of why they gained weight by using these new weight loss drugs.
Deception
(30%)
The article is deceptive in several ways. Firstly, the author presents Ozempic and Mounjaro as game changers for weight loss without providing any evidence to support this claim. Secondly, the author quotes Dr. Leatherman stating that people looking to quickly lose weight won't address the root causes of why they gained weight, but fails to provide any evidence or studies supporting this statement. Thirdly, the article presents side effects as a concern for patients without providing any information on how common these side effects are or what their severity is.
Dr. Leatherman quotes stating that people looking to quickly lose weight won't address the root causes of why they gained weight, but fails to provide any evidence or studies supporting this statement.
The article presents side effects as a concern for patients without providing any information on how common these side effects are or what their severity is.
The author states that Ozempic and Mounjaro are game changers for weight loss without providing any evidence to support this claim.
Fallacies
(70%)
The article discusses the potential side effects of weight loss drugs Ozempic and Mounjaro. The author presents an expert's perspective on these drugs, highlighting their risks as well as their benefits. However, there are a few fallacies present in the article that could be improved upon.
The statement 'FDA approved but always remember too that when things get pulled off the market by the FDA, they were once approved by the FDA' is an appeal to authority fallacy. The author presents this as a fact without providing any evidence or context for it.
Bias
(85%)
The article discusses the potential side effects of weight loss drugs Ozempic and Mounjaro. The author Laura Hussey presents a balanced view by discussing both the benefits and risks of these medications. However, there are some examples that suggest bias in her reporting.
> Drugs like Ozempic and Mounjaro are game changers for some people trying to lose weight.
. U.S.WorldBusinessArtsLifestyleOpinionAudioGamesCookingWirecutterThe Athletic You have a preview view of this article while we are checking your access.
. Credit...Photo Illustration by Matt Chase The new obesity drugs might be an exception to a chronic, deadly problem: the failure to stick with medication.
It's a problem that doctors call nonadherence — the common human tendency to resist medical treatment — and it leads to countless deaths and billions of dollars of preventable medical costs each year.
. Though it’s still early days, and there is a paucity of data on compliance with the new drugs, doctors say they are noticing another astounding effect: Patients seem to take them faithfully, week in and week out.
Accuracy
Some patients may have to get over an initial reluctance to start. A national survey showed that when people were told they would gain weight back if they stopped taking the drugs, most lost interest in starting them.
Deception
(30%)
The article is deceptive in several ways. Firstly, the author claims that most people don't take their medication but provides no evidence to support this claim. Secondly, the author states that patients seem to take obesity drugs faithfully without providing any data or studies on compliance rates for these specific medications.
The article makes a blanket statement about people not taking their medication without providing any evidence:
Fallacies
(85%)
The article contains several fallacies. The author uses an appeal to authority by stating that doctors call nonadherence the common human tendency to resist medical treatment and leads to countless deaths and billions of dollars of preventable medical costs each year without providing any evidence or citation for this claim.
Doctors say they are noticing another astounding effect: Patients seem to take them faithfully, week in and week out.
Bias
(85%)
The article is biased towards the new obesity drugs Wegovy and Zepbound. The author uses language that depicts these drugs as an exception to a chronic problem of nonadherence, which implies that other medications are not effective or have low compliance rates. Additionally, the author quotes patients who express faithfulness in taking these specific drugs without providing any context for their experiences with other medications.
The new obesity drugs might be an exception to a chronic, deadly problem: the failure to stick with medication.
